title: Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma: A case report.
abstract: BACKGROUND
  Cutaneous composite lymphomas are very rare. Their treatment depends upon the different contributing lymphoma entities. Peripheral T-cell lymphoma, not otherwise specified, (PTCL-NOS) represents an aggressive lymphoma subtype. Follicular cutaneous B-cell lymphoma (FCBCL) runs an indolent course. Treatment with pegylated liposomal encapsulated doxorubicin (PLE-DOXO) has yet not been reported in this entity.
  
  
  METHODS
  A 73-year-old male patient presented with 3 rapidly growing, painful nodules on his left leg. He was diagnosed as composite cutaneous lymphoma consisting of PTCL-NOS and FCBCL. All lesions had been surgically removed. Staging was unremarkable. After 4 months a relapse occurred with involvement of inguinal lymph nodes and systemic treatment with PEL-DOXO 20 mg/ m every 3 weeks was initiated. After 6 cycles PLE-DOXO, which were well tolerated without grade 3 or 4 toxicities, a mixed response was obtained with complete remission of cutaneous lesions.Lymph nodes were treated by radiotherapy. A second relapse occurred after 8 months and various polychemotherapy regimens were applied without remission. The overall survival was 28 months.
  
  
  CONCLUSIONS
  PEL-DOXO is a possible initial systemic treatment in case of PCTL-NOS. Whether polychemotherapy offers an advantage for survival remains questionable but further investigations are needed.
authors: Department of Dermatology and Allergology, Insitute of Pathology "Georg Schmorl", Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.
authors: Uwe
authors: U
authors: Wollina
authors: Dana
authors: D
authors: Langner
authors: Gesina
authors: G
authors: Hansel
authors: Gunter
authors: G
authors: Haroske
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D001706:Biopsy; D058617:Composite Lymphoma / Q000175:diagnosis / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011092:Polyethylene Glycols / Q000008:administration & dosage; D012074:Remission Induction; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed
chemical_list: D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin